The content on this site is intended for healthcare professionals only
The Rwanda FDA regulates medicines through robust pharmacovigilance and clinical trial systems, including post-marketing surveillance to ensure the safety of medical products.
Both electronic and paper-based tools are used to report adverse events, and international databases are accessed as part of the International Drug Monitoring System. Advisory committees assist with risk assessments, while public health programs, healthcare institutions, and the academic sector play a key role in safety monitoring.
Marketing authorisation holders are responsible for managing risks and reporting safety issues in accordance with clear and timely communication guidelines.
Best practice in precision medicine for prostate cancer
Burden and trends of breast cancer worldwide: Opportunities for prevention?
Bone-protective agents given with enzalutamide with or without radium-223 show greater survival benefits in mCRPC
Patterns and correlates of multiple tobacco product use among people with HIV in India
Exploring the National Access Subcutaneous Trastuzumab Program in Kenya
Geriatric interventions are beneficial in reducing treatment-related toxicity in older adults with cancer
New classification for identifying HR myeloma based on cytogenetic abnormalities
Gaza's cancer patients: Navigating the dual struggle of illness and war
WCI's role in the prevention of tobacco related cancer among Beedi rolling women in India
